Меню
Идёт набор NCT07499674

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

Фаза III С лечением Lung Cancer Lung Metastases

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Abenacianine, Near Infrared (NIR) Imaging.
Кому может быть актуально
Состояния в реестре: Lung Cancer, Lung Metastases. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США, Австралия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

A Phase 3, Multi-center, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Abenacianine (VGT-309), a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung - VISUALIZE 2

Обзор

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.

Вмешательства

  • Препарат Abenacianine
    Intravenous drug to be given by syringe pump.
  • Другое Near Infrared (NIR) Imaging
    NIR imaging is a non-visible, optical technique capturing light just beyond human vision, allowing high-contrast imaging.

Первичные конечные точки

  • Identify the proportion of participants with at least one Clinically Significant Event (CSE) as defined by: [Срок оценки: Day of Surgery]
Вторичные конечные точки (4)
  • Key Secondary Endpoints [Срок оценки: Upon receipt of histopathology report (~2-3 weeks post surgery)]
  • Key Secondary [Срок оценки: Upon receipt of histopathology report. (~2-3 weeks post surgery)]
  • Key Secondary [Срок оценки: Upon receipt of histopathology report. (~2-3 weeks post surgery)]
  • Other Secondary Endpoints [Срок оценки: Day of surgery]

Критерии участия

Критерии включения

  • Be willing and able to sign the informed consent and comply with study procedures.
  • Be at least 18 years of age.
  • Be scheduled for or planning to have a surgical resection of a lung lesion or mass with diagnostic and/or curative intent.
  • Meet all requirements for the planned surgery based on opinion of the surgeon, anesthesiologist, and/or other consulting physician.
  • Be able to meet the following conditions:
  • Female participants must be of non-childbearing potential, or,
  • If of childbearing potential, be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30 after treatment.
  • Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days after dosing.
  • Have not participated in an interventional clinical trial within the last 30 days.

Критерии исключения

  • They have a known allergy or reaction to radiographic contrast agents, ICG, or any component of abenacianine.
  • They have received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study enrollment.
  • They have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.
  • They are prisoners, institutionalized individuals, or are unable to consent for themselves.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Двойное слепое
Основная цель
Лечение

Центры проведения

США · 8 центров
  • City of Hope National Medical Center — Duarte
  • Hoag Memorial Hospital Presbyterian — Newport Beach
  • University of Colorado Hospital — Aurora
  • Orlando Health Cancer Center — Orlando
  • University of Michigan — Ann Arbor
  • Mayo Clinic — Rochester
  • Hospital of the University of Pennsylvania — Philadelphia
  • University of Texas, MD Anderson Cancer Center — Houston
Австралия · 1 центр
  • St. Vincent's Hospital — Fitzroy

Идентификаторы

NCT: NCT07499674 · VGT-309-3-2025

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗